|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||26.75 - 26.75|
|52-week range||25.50 - 32.10|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||22.23|
|Forward dividend & yield||0.44 (1.65%)|
|Ex-dividend date||10 May 2021|
|1y target est||N/A|
After discussing a potential deal since March, the companies were now in advanced talks and CSL, the world's largest maker of blood plasma treatments, was carrying out due diligence on the Swiss firm, according to reports in The Australian Financial Review and The Australian. Both Vifor Pharma and CSL said in separate statements that they will not comment on the speculation. Morgan Stanley analysts said in a research note that CSL may be seeking diversification because blood plasma collections - where it pays people to give blood, which it then converts to treatments - remained depressed due to COVID-19 restrictions.
CCXI earnings call for the period ending September 30, 2021.
Please be advised that this call is being recorded at Cara's request. This is Will Gramig with Stern Investor Relations, and welcome to Cara Therapeutics' third quarter 2021 financial results and update conference call. Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.